Upper gastrointestinal event risk with COX-2 inhibitors depended on known risk factors - Commentary

David A Henry, Patricia McGettigan

Research output: Contribution to journalComment/debateResearch

Abstract

[Extract] The risk for serious GI complications from NSAIDs is known to be
greater in certain at-risk groups, such as elderly persons and those with
serious chronic diseases. This is because their background risk is high, so
the additional effect of NSAIDs results in a greater excess risk. Until now,
the belief that the relative safety of cyclooxygenase 2 (COX-2) selective
inhibitors compared with nonselective NSAIDs is greatest in such highrisk groups has been based on assumptions rather than evidence. This reanalysis by Laine and colleagues of the VIOXX Gastrointestinal
Outcomes Research (VIGOR) trial comparing rofecoxib with naproxen
confirms the advantage of the more selective drug in high-risk patients.
Original languageEnglish
Pages (from-to)51
JournalACP Journal Club
Volume138
Issue number2
Publication statusPublished - 2003
Externally publishedYes

Fingerprint

Cyclooxygenase 2 Inhibitors
Non-Steroidal Anti-Inflammatory Agents
Cyclooxygenase 2
Chronic Disease
Safety
Research
Pharmaceutical Preparations

Cite this

@article{24215b6c3bd04e76896e67f6bafeef5b,
title = "Upper gastrointestinal event risk with COX-2 inhibitors depended on known risk factors - Commentary",
abstract = "[Extract] The risk for serious GI complications from NSAIDs is known to begreater in certain at-risk groups, such as elderly persons and those withserious chronic diseases. This is because their background risk is high, sothe additional effect of NSAIDs results in a greater excess risk. Until now,the belief that the relative safety of cyclooxygenase 2 (COX-2) selectiveinhibitors compared with nonselective NSAIDs is greatest in such highrisk groups has been based on assumptions rather than evidence. This reanalysis by Laine and colleagues of the VIOXX GastrointestinalOutcomes Research (VIGOR) trial comparing rofecoxib with naproxenconfirms the advantage of the more selective drug in high-risk patients.",
author = "Henry, {David A} and Patricia McGettigan",
year = "2003",
language = "English",
volume = "138",
pages = "51",
journal = "ACP Journal Club",
issn = "1056-8751",
publisher = "American College of Physicians",
number = "2",

}

Upper gastrointestinal event risk with COX-2 inhibitors depended on known risk factors - Commentary. / Henry, David A; McGettigan, Patricia.

In: ACP Journal Club, Vol. 138, No. 2, 2003, p. 51.

Research output: Contribution to journalComment/debateResearch

TY - JOUR

T1 - Upper gastrointestinal event risk with COX-2 inhibitors depended on known risk factors - Commentary

AU - Henry, David A

AU - McGettigan, Patricia

PY - 2003

Y1 - 2003

N2 - [Extract] The risk for serious GI complications from NSAIDs is known to begreater in certain at-risk groups, such as elderly persons and those withserious chronic diseases. This is because their background risk is high, sothe additional effect of NSAIDs results in a greater excess risk. Until now,the belief that the relative safety of cyclooxygenase 2 (COX-2) selectiveinhibitors compared with nonselective NSAIDs is greatest in such highrisk groups has been based on assumptions rather than evidence. This reanalysis by Laine and colleagues of the VIOXX GastrointestinalOutcomes Research (VIGOR) trial comparing rofecoxib with naproxenconfirms the advantage of the more selective drug in high-risk patients.

AB - [Extract] The risk for serious GI complications from NSAIDs is known to begreater in certain at-risk groups, such as elderly persons and those withserious chronic diseases. This is because their background risk is high, sothe additional effect of NSAIDs results in a greater excess risk. Until now,the belief that the relative safety of cyclooxygenase 2 (COX-2) selectiveinhibitors compared with nonselective NSAIDs is greatest in such highrisk groups has been based on assumptions rather than evidence. This reanalysis by Laine and colleagues of the VIOXX GastrointestinalOutcomes Research (VIGOR) trial comparing rofecoxib with naproxenconfirms the advantage of the more selective drug in high-risk patients.

M3 - Comment/debate

VL - 138

SP - 51

JO - ACP Journal Club

JF - ACP Journal Club

SN - 1056-8751

IS - 2

ER -